Matthew D Onsum

Title: Inventor Spotlight: Matthew D Onsum

Introduction

Matthew D Onsum, a prominent inventor based in El Cerrito, California, has made significant contributions to the field of biotechnology. With an impressive portfolio of 15 patents, his work primarily focuses on innovative methods for treating skin tissue damage through novel bi-specific proteins.

Latest Patents

Among his latest patents, Matthew D Onsum has developed groundbreaking techniques such as the "Method of treating skin tissue damage by topically administering a bi-specific protein comprising a human insulin-like growth factor variant and a human annexin A5 variant." This patent emphasizes the therapeutic potential of bi-specific fusion proteins and encapsulates pharmaceutical compositions that utilize these proteins to repair or regenerate damaged or diseased tissue. Another notable patent includes the development of "Bi-specific therapeutic proteins, in vivo methods of use thereof and encoding nucleic acids thereof," which further enhances the applications of bi-specific fusion proteins in medical treatments.

Career Highlights

Throughout his career, Matthew D Onsum has worked with esteemed companies such as Silver Creek Pharmaceuticals, Inc. and Merrimack Pharmaceuticals, Inc. His experiences in these organizations have enabled him to refine his innovative ideas and advance research in biopharmaceuticals, particularly in the realm of tissue repair and regeneration.

Collaborations

In his professional journey, Matthew has had the opportunity to collaborate with notable individuals in the industry, including Ulrik Bjerl Nielsen and Birgit Schoeberl. These collaborations have fostered a dynamic exchange of ideas and have played a pivotal role in the advancement of his research initiatives.

Conclusion

Matthew D Onsum stands out as a remarkable inventor in the biotechnology sector. His dedication to developing innovative therapeutic solutions reflects his commitment to improving patient outcomes and advancing medical science. With his continued work and patent innovations, he is likely to remain a key figure in the evolution of biopharmaceutical therapies.